HEOR, Market Access, IT, and Clinical innovators throughout the healthcare ecosystem are turning to real world evidence (RWE) to develop greater insight into the value of drugs, translational medicine and patient outcomes.
With FDA’s Janet Woodcock making a statement that “the clinical trials system is broken,” coupled with a rise in RWE initiatives by regulatory agencies – including the 21st Century Cures Act and the IMI GetReal project – the need to leverage RWE to establish the value and validity of drugs has taken on greater urgency for organizations across the ecosystem. To prove the safety, efficacy, and usefulness of their products, leaders in the life sciences employ real world evidence to:
- Go from cohort level proof to individual outcomes
- Build predictive simulations and improve protocol design
- Derive critical insight into the value of drugs and treatments
Data is the Lifeblood of Your Efforts
From electronic health records (EHRs) to wearable devices, the ability to rapidly and securely integrate every type of real world data (RWD) for analysis is key to reducing the time required to develop RWE. Unfortunately, RWD itself presents a formidable hurdle to insight because it is multi-structured, unstructured, and stored in disconnected silos, (e.g., claims data, registries, patient health surveys, etc.) that make search and discovery efforts an acutely painful real world challenge.
The success of RWE development efforts will be driven by your organization’s ability to efficiently integrate, harmonize, and analyze disparate data sets. Equipped with an agile, secure technology platform, you can extract more value from your RWD with less time and cost.
Bill Fox, CTO of Healthcare and Life Sciences, MarkLogic
Bill Fox, JD MA, is Global CTO of Global Healthcare, Life Sciences and Insurance at MarkLogic. Bill is known as a nationally recognized healthcare, life sciences, insurance, data strategy and analytics business leader. A former State and Federal prosecutor, law firm partner, consultant and technology executive, he has established a reputation as a leading voice on issues related to healthcare analytics, big data, payment integrity, data security, compliance, strategy and risk.
Anita Burrell, Founder and CEO, Anita Burrell Consulting LLC
Anita Burrell has 23 years of leadership experience in the pharmaceutical industry in a wide variety of roles and geographies. Anita has helped companies understand market dynamics and payer behavior in diabetes and MS, including designing big data platforms to deliver value in terms of regional sales variations, develop predictive models to inform HTA submissions, and understand the implications of digital health and possibilities to use behavioural economics.
Who Should Attend?
Senior professionals from biopharmaceutical and medical device companies involved in:
- Data Analytics / Bioinformatics
- Drug Safety / Pharmacovigilance
- Health Economics & Outcomes Research (HEOR)
- Market Access
- Regulatory Affairs
- Scientific Affairs
- Data Architecture / Solutions Architecture / Enterprise Architecture
- Brand Management
What You Will Learn
Join market access and real world evidence expert, Anita Burrell, and MarkLogic CTO, Bill Fox, for this eye-opening webinar that will offer insight into:
- Efficiently integrating real world data from disparate sources
- Accelerating development of real world evidence
- Enhancing insight for healthcare decision-making
As the world’s best database for integrating data from silos, MarkLogic’s database platform empowers our customers to be more agile and cost efficient, advancing development and delivery of RWE to expedite pre- and post-regulatory approval processes. Life Sciences organizations trust MarkLogic to help accelerate the development and availability of new drug therapies and medical devices.